时迈药业拟赴香港上市;映恩生物治疗恶性实体瘤创新药获批临床丨医药早参

每日经济新闻
11 hours ago

丨 2025年11月14日星期五丨  NO.1 时迈药业拟赴香港上市  港交所官网显示,浙江时迈药业递交上市申请,华泰国际为独家保荐人。据悉,时迈药业成立于2017年,作为下一代T细胞衔接器(TCE)疗法的先驱企业,旨在利用并引导人体免疫系统对抗癌症的下一代免疫疗法,公司已开发下一代先锋疗法遮蔽型TCE,可在肿瘤中被选择性激活,用于治疗实体瘤。目前,时迈药业拥有四款自主研发的临床阶段的候选药物。 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10